Telix Pharmaceuticals (NASDAQ:TLX) Sees Unusually-High Trading Volume - What's Next?

Key Points

• Telix Pharmaceuticals (NASDAQ:TLX) experienced a significant increase in trading volume, with 82,897 shares exchanged, marking a 35% rise from the previous session.
• Analysts have a consensus "Moderate Buy" rating for TLX, with a price target averaging around $22.33, supported by recent upgrades from firms like Wedbush and HC Wainwright.
• Large institutional investors have been acquiring positions in Telix Pharmaceuticals, with at least five firms purchasing new stakes during recent quarters, indicating growing interest in the stock.

Telix Pharmaceuticals Limited (NASDAQ:TLX - Get Free Report) shares saw unusually-high trading volume on Tuesday . Approximately 82,897 shares traded hands during trading, an increase of 35% from the previous session's volume of 61,593 shares.The stock last traded at $9.21 and had previously closed at $9.05.

Wall Street Analysts Forecast Growth

TLX has been the topic of several recent analyst reports. William Blair restated an "outperform" rating on shares of Telix Pharmaceuticals in a report on Wednesday, July 9th. JPMorgan Chase & Co. reiterated a "neutral" rating on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Wedbush reiterated an "outperform" rating and issued a $22.00 target price on shares of Telix Pharmaceuticals in a report on Thursday, August 28th. Finally, HC Wainwright dropped their target price on Telix Pharmaceuticals from $23.00 to $20.00 and set a "buy" rating on the stock in a report on Wednesday. Four investment analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $21.33.

Telix Pharmaceuticals Price Performance

The firm has a 50-day moving average price of $12.54 and a two-hundred day moving average price of $15.41. The company has a debt-to-equity ratio of 0.99, a current ratio of 2.78 and a quick ratio of 2.66.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Pier Capital LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $3,037,000. Russell Investments Group Ltd. acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $975,000. Jane Street Group LLC acquired a new stake in shares of Telix Pharmaceuticals in the second quarter valued at $564,000. ABC Arbitrage SA acquired a new stake in shares of Telix Pharmaceuticals in the first quarter valued at $451,000. Finally, Vanguard Personalized Indexing Management LLC bought a new position in Telix Pharmaceuticals in the second quarter valued at about $297,000.

Telix Pharmaceuticals Company Profile

Telix Pharmaceuticals Limited. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.